Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Is there role of HER2 directed therapy in adjuvant treatment of colon adenocarcinoma for tumors that are HER2 3+ by IHC?
Related Questions
Are there long-term toxicity and QOL considerations for patients receiving nivo/ipi compared to checkpoint monotherapy that would impact your treatment decisions for first line metastatic MSI-H/dMMR CRC?
How do CheckMate 8HW results impact your sequencing of available therapies in dMMR/MSI-H metastatic colorectal cancer?
Is there a role for stents for patients with a new diagnosis of metastatic upper rectal cancer with a near-obstructing primary?
In pts with HCC who initially achieved a good response on durvalumab/tremelimumab , but later lost it, would you consider rechallenging with tremelimumab ?
How do you best incorporate use of filgrastim/pegfilgrastim in capecitabine based regimens?
In a patient with metastatic colorectal cancer to the lung and liver, is there a role for liver directed therapy if the lung is not amenable to local therapy?
Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?
Are you incorporating TTFields into treatment protocols for locally advanced pancreatic cancer based on the PANOVA-3 study?
How would you approach first-line treatment for a patient with metastatic colon cancer who develops an anaphylactic reaction to cetuximab with FOLFOX/cetuximab/encorafenib?
What systemic therapy would you use in patients with gastric cancer who had a relapse after Durva-FLOT (MATTERHORN regimen)?
